2026-06-18T03:36:53Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88222024-03-15T01:05:27Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

00925njm 22002777a 4500 dc Santos García, Diego author Deus-Fonticoba, Teresa de author Cores Bartolomé, Carlos author Feal Painceiras, María author Suárez Castro, Ester author Canfield, Héctor author Martínez Miró, Cristina author Jesús, Silvia author Aguilar, Miquel author Pastor, Pau author Planellás, Lluis L. author Cosgaya, Marina author García Caldentey, Juan author Caballol, Núria author Legarda, Inés author Hernández Vara, Jorge author Cabo López, Iria author López Manzanares, Lydia author González Aramburu, Isabel author Ávila Rivera, María A. author Gómez Mayordomo, Víctor author Nogueira, Víctor author Puente, Víctor author Dotor, Julio author Borrue, Carmen author Solano Vila, Berta author Álvarez Saúco, María author Vela Desojo, Lydia author Escalante Arroyo, Sonia author Cubo Delgado, Esther author Carrillo Padilla, Francisco author Martínez Castrillo, Juan Carlos author Sánchez Alonso, Pilar author Alonso Losada, María Gema author López Ariztegui, Nuria author Gastón, Itziar author Kulisevsky Bojarsky, Jaume author Blázquez Estrada, Marta author Seijo, Manuel author Ruíz Martínez, Javier author Valero, Caridad author Kurtis, Mónica M. author Fabregues, Oriol de author González Ardura, Jessica author Alonso Redondo, Rubén author Ordás Bandera, Carlos Manuel author López Díaz, Luis M. author McAfee, Darrian author Martínez Martín, Pablo author Mir, Pablo author COPPADIS Study Group author 2022-05 Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson’s disease (PD) patients regarding the development of motor fluctuations (MF). Methods: PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Results: Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. Conclusions: In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up. http://hdl.handle.net/10259/8822 10.3390/diagnostics12051147 2075-4418 Burden Follow-up Non-motor symptoms Motor fluctuations Parkinson’s disease Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study